Incyte says Phase 3 HS trial shows durable 54-week response for povorcitinib

Reuters03-29 03:00

Incyte says Phase 3 HS trial shows durable 54-week response for povorcitinib

Incyte disclosed new 54-week Phase 3 data for oral JAK1 inhibitor povorcitinib in moderate-to-severe hidradenitis suppurativa, scheduled for late-breaking presentation March 28 at 2026 American Academy of Dermatology Annual Meeting.
Across STOP-HS1 and STOP-HS2, up to 71.4% of patients achieved HiSCR50 through Week 54.
More stringent endpoints also improved, with up to 57% reaching HiSCR75, up to 29% reaching HiSCR100.
Safety through Week 54 remained consistent with previously presented 24-week results, with treatment-emergent adverse events reported in 76.2% to 83.4% of patients.
Data supported regulatory filings, with povorcitinib applications under review by FDA and European Medicines Agency for hidradenitis suppurativa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260328441699) on March 28, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623433888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-29 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623433888","market":"nz","top_or_hot":-1,"title":"Incyte says Phase 3 HS trial shows durable 54-week response for povorcitinib","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte says Phase 3 HS trial shows durable 54-week response for povorcitinib\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Incyte disclosed new 54-week Phase 3 data for oral JAK1 inhibitor povorcitinib in moderate-to-severe hidradenitis suppurativa, scheduled for late-breaking presentation March 28 at 2026 American Academy of Dermatology Annual Meeting.\n        </li>\n<li>\n          Across STOP-HS1 and STOP-HS2, up to 71.4% of patients achieved HiSCR50 through Week 54.\n        </li>\n<li>\n          More stringent endpoints also improved, with up to 57% reaching HiSCR75, up to 29% reaching HiSCR100.\n        </li>\n<li>\n          Safety through Week 54 remained consistent with previously presented 24-week results, with treatment-emergent adverse events reported in 76.2% to 83.4% of patients.\n        </li>\n<li>\n          Data supported regulatory filings, with povorcitinib applications under review by FDA and European Medicines Agency for hidradenitis suppurativa.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260328441699) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte says Phase 3 HS trial shows durable 54-week response for povorcitinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte says Phase 3 HS trial shows durable 54-week response for povorcitinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-29 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte says Phase 3 HS trial shows durable 54-week response for povorcitinib\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Incyte disclosed new 54-week Phase 3 data for oral JAK1 inhibitor povorcitinib in moderate-to-severe hidradenitis suppurativa, scheduled for late-breaking presentation March 28 at 2026 American Academy of Dermatology Annual Meeting.\n        </li>\n<li>\n          Across STOP-HS1 and STOP-HS2, up to 71.4% of patients achieved HiSCR50 through Week 54.\n        </li>\n<li>\n          More stringent endpoints also improved, with up to 57% reaching HiSCR75, up to 29% reaching HiSCR100.\n        </li>\n<li>\n          Safety through Week 54 remained consistent with previously presented 24-week results, with treatment-emergent adverse events reported in 76.2% to 83.4% of patients.\n        </li>\n<li>\n          Data supported regulatory filings, with povorcitinib applications under review by FDA and European Medicines Agency for hidradenitis suppurativa.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260328441699) on March 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"红杉资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL7cHfRm:1","article_id":"2623433888","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623433888","pubTimestamp":1774724438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incyte disclosed new 54-week Phase 3 data for oral JAK1 inhibitor povorcitinib in moderate-to-severe hidradenitis suppurativa, scheduled for late-breaking presentation March 28 at 2026 American Academy of Dermatology Annual Meeting.Across STOP-HS1 and STOP-HS2, up to 71.4% of patients achieved HiSCR50 through Week 54.More stringent endpoints also improved, with up to 57% reaching HiSCR75, up to 29% reaching HiSCR100.Safety through Week 54 remained consistent with previously presented 24-week results, with treatment-emergent adverse events reported in 76.2% to 83.4% of patients.Data supported regulatory filings, with povorcitinib applications under review by FDA and European Medicines Agency for hidradenitis suppurativa.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","BK4588":"碎股","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4532":"文艺复兴科技持仓"},"translate_title":"Incyte表示3期HS试验显示povorcitinib可持续54周反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"Incyte says Phase 3 HS trial shows durable 54-week response for povorcitinib\n    \n\n\n          Incyte disclosed new 54-week Phase 3 data for oral JAK1 inhibitor povorcitinib in moderate-to-severe hidradenitis suppurativa, scheduled for late-breaking presentation March 28 at 2026 American Academy of Dermatology Annual Meeting.\n        \n\n          Across STOP-HS1 and STOP-HS2, up to 71.4% of patients achieved HiSCR50 through Week 54.\n        \n\n          More stringent endpoints also improved, with up to 57% reaching HiSCR75, up to 29% reaching HiSCR100.\n        \n\n          Safety through Week 54 remained consistent with previously presented 24-week results, with treatment-emergent adverse events reported in 76.2% to 83.4% of patients.\n        \n\n          Data supported regulatory filings, with povorcitinib applications under review by FDA and European Medicines Agency for hidradenitis suppurativa.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260328441699) on March 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623433888","isCrawlerRequest":true}